Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro
about
Anti-Epstein-Barr virus (EBV) activity of beta-L-5-iododioxolane uracil is dependent on EBV thymidine kinaseAnti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2',3'-didehydro-2',3'-dideoxythymidine in cells.Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.Mitochondrial toxicity and HIV therapy.Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture.Retention of metabolites of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cellsNovel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity.HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.
P2860
Q28344936-37F699C5-8CF3-46DB-8EE5-C4782EFEB20EQ28379623-D77171B3-8C5A-4FA3-995C-AE5B9D74922BQ33769957-2F4FDF52-79D4-4F8E-85AC-3EBB482D70B7Q33978482-4089129D-E63F-4E36-A609-50951F9F254FQ34279271-35B3F48E-7822-48B9-B3FB-974A76728E46Q36295462-C31D8E5F-EF10-4657-98BF-DE50444025C0Q37199040-E86111BE-0C2C-4F66-85F3-54F4DB649C7CQ37274775-286732DA-3950-4246-839F-08C1B1D1B3F1Q37734538-39295122-E512-4EEE-8E43-534160B22B76Q41879018-BA22737F-F2DD-4724-A3E8-8E9C3A6C9E7C
P2860
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Metabolism of 2',3'-dideoxy-2' ...... +) nucleoside analogs in vitro
@ast
Metabolism of 2',3'-dideoxy-2' ...... +) nucleoside analogs in vitro
@en
Metabolism of 2',3'-dideoxy-2' ...... +) nucleoside analogs in vitro
@nl
type
label
Metabolism of 2',3'-dideoxy-2' ...... +) nucleoside analogs in vitro
@ast
Metabolism of 2',3'-dideoxy-2' ...... +) nucleoside analogs in vitro
@en
Metabolism of 2',3'-dideoxy-2' ...... +) nucleoside analogs in vitro
@nl
prefLabel
Metabolism of 2',3'-dideoxy-2' ...... +) nucleoside analogs in vitro
@ast
Metabolism of 2',3'-dideoxy-2' ...... +) nucleoside analogs in vitro
@en
Metabolism of 2',3'-dideoxy-2' ...... +) nucleoside analogs in vitro
@nl
P2093
P2860
P1476
Metabolism of 2',3'-dideoxy-2' ...... +) nucleoside analogs in vitro
@en
P2093
E G Bridges
G E Dutschman
M Kukhanova
P2860
P304
P407
P577
1998-07-01T00:00:00Z